These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36185276)

  • 121. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells.
    Zhu S; Denman CJ; Cobanoglu ZS; Kiany S; Lau CC; Gottschalk SM; Hughes DP; Kleinerman ES; Lee DA
    Pharm Res; 2015 Mar; 32(3):779-92. PubMed ID: 24203492
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
    Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
    Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
    [TBL] [Abstract][Full Text] [Related]  

  • 123. The Oncoprotein SKI Acts as A Suppressor of NK Cell-Mediated Immunosurveillance in PDAC.
    Ponath V; Frech M; Bittermann M; Al Khayer R; Neubauer A; Brendel C; Pogge von Strandmann E
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33023028
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.
    Chuah S; Lee J; Song Y; Kim HD; Wasser M; Kaya NA; Bang K; Lee YJ; Jeon SH; Suthen S; A'Azman S; Gien G; Lim CJ; Chua C; Hazirah SN; Lee HK; Lim JQ; Lim TKH; Yeong J; Chen J; Shin EC; Albani S; Zhai W; Yoo C; Liu H; Choo SP; Tai D; Chew V
    J Hepatol; 2022 Sep; 77(3):683-694. PubMed ID: 35430299
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy.
    Deng ZJ; Li L; Teng YX; Zhang YQ; Zhang YX; Liu HT; Huang JL; Liu ZX; Ma L; Zhong JH
    J Clin Transl Hepatol; 2022 Feb; 10(1):147-158. PubMed ID: 35233384
    [TBL] [Abstract][Full Text] [Related]  

  • 126. A Novel Prognostic Biomarker LPAR6 in Hepatocellular Carcinoma via Associating with Immune Infiltrates.
    He J; Meng M; Wang H
    J Clin Transl Hepatol; 2022 Feb; 10(1):90-103. PubMed ID: 35233377
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Clinical Studies on Ultrafractionated Chemoradiation: A Systematic Review.
    Scirocco E; Cellini F; Zamagni A; Macchia G; Deodato F; Cilla S; Strigari L; Buwenge M; Rizzo S; Cammelli S; Morganti AG
    Front Oncol; 2021; 11():748200. PubMed ID: 34868948
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Hepatic Resection Versus Stereotactic Body Radiation Therapy Plus Transhepatic Arterial Chemoembolization for Large Hepatocellular Carcinoma: A Propensity Score Analysis.
    Sun J; Li WG; Wang Q; He WP; Wang HB; Han P; Zhang T; Zhang AM; Fan YZ; Sun YZ; Duan XZ
    J Clin Transl Hepatol; 2021 Oct; 9(5):672-681. PubMed ID: 34722182
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Differential Effects of Histone Deacetylases on the Expression of NKG2D Ligands and NK Cell-Mediated Anticancer Immunity in Lung Cancer Cells.
    Cho H; Son WC; Lee YS; Youn EJ; Kang CD; Park YS; Bae J
    Molecules; 2021 Jun; 26(13):. PubMed ID: 34203519
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade.
    Bozward AG; Warricker F; Oo YH; Khakoo SI
    Front Immunol; 2021; 12():643310. PubMed ID: 33995362
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Enlightening the Immune Mechanism of the Abscopal Effect in a Murine HCC Model and Overcoming the Late Resistance With Anti-PD-L1.
    Park JH; Kim HY; Lee A; Seo YK; Kim IH; Park ET; Kang MS; Park SJ; Park S
    Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):510-520. PubMed ID: 33383126
    [TBL] [Abstract][Full Text] [Related]  

  • 132. Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan.
    Shao YY; Wang SY; Lin SM; ;
    J Formos Med Assoc; 2021 Apr; 120(4):1051-1060. PubMed ID: 33199101
    [TBL] [Abstract][Full Text] [Related]  

  • 133. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond.
    Lee YH; Tai D; Yip C; Choo SP; Chew V
    Front Immunol; 2020; 11():568759. PubMed ID: 33117354
    [TBL] [Abstract][Full Text] [Related]  

  • 134. Immunomodulation of NK Cells by Ionizing Radiation.
    Chen J; Liu X; Zeng Z; Li J; Luo Y; Sun W; Gong Y; Zhang J; Wu Q; Xie C
    Front Oncol; 2020; 10():874. PubMed ID: 32612950
    [TBL] [Abstract][Full Text] [Related]  

  • 135. MICAgen Mice Recapitulate the Highly Restricted but Activation-Inducible Expression of the Paradigmatic Human NKG2D Ligand MICA.
    Kim Y; Born C; Bléry M; Steinle A
    Front Immunol; 2020; 11():960. PubMed ID: 32582150
    [TBL] [Abstract][Full Text] [Related]  

  • 136. Natural killer group 2D receptor and its ligands in cancer immune escape.
    Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
    Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
    [TBL] [Abstract][Full Text] [Related]  

  • 137. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
    Bray F; Ferlay J; Soerjomataram I; Siegel RL; Torre LA; Jemal A
    CA Cancer J Clin; 2018 Nov; 68(6):394-424. PubMed ID: 30207593
    [TBL] [Abstract][Full Text] [Related]  

  • 138. NK cells for PD-1/PD-L1 blockade immunotherapy: pinning down the NK cell.
    Dunai C; Murphy WJ
    J Clin Invest; 2018 Oct; 128(10):4251-4253. PubMed ID: 30198909
    [TBL] [Abstract][Full Text] [Related]  

  • 139. Ultrasound-guided radiofrequency ablation enhances natural killer-mediated antitumor immunity against liver cancer.
    Mo Z; Lu H; Mo S; Fu X; Chang S; Yue J
    Oncol Lett; 2018 May; 15(5):7014-7020. PubMed ID: 29725428
    [TBL] [Abstract][Full Text] [Related]  

  • 140. Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells.
    Bugide S; Green MR; Wajapeyee N
    Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3509-E3518. PubMed ID: 29581297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.